Drugs

Gene Therapy for Restenosis: Current Status
pp. 1575-1585(11)
Authors: Rutanen J.; Markkanen J.; Ylä-Herttuala S.

Single-Agent Immunosuppression After Liver Transplantation: What is Possible?
pp. 1587-1597(11)
Authors: Raimondo M.L.; Burroughs A.K.

Cardiovascular Risk Profile of Antirheumatic Agents in Patients with Osteoarthritis and Rheumatoid Arthritis
pp. 1599-1609(11)
Authors: Nurmohamed M.T.; van Halm V.P.; Dijkmans B.A.C.

Ocular Allergy Guidelines: A Practical Treatment Algorithm
pp. 1611-1634(24)
Author: Bielory L.

Generalised Anxiety Disorder: Treatment Options
pp. 1635-1648(14)
Authors: Sramek J.J.; Zarotsky V.; Cutler N.R.

Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death
pp. 1649-1671(23)
Authors: Haddad P.M.; Anderson I.M.

Fondaparinux Sodium
pp. 1673-1685(13)
Authors: Keam S.J.; Goa K.L.

Fondaparinux Sodium: A Viewpoint by Alexander G. G. Turpie
pp. 1686-1687(2)
Author: Turpie A.G.G.

Fondaparinux Sodium: A Viewpoint by Alexander S. Gallus
pp. 1686-1687(2)
Author: Gallus A.S.

Balsalazide: A Review of its Therapeutic Use in Mild-to-Moderate Ulcerative Colitis
pp. 1689-1705(17)
Authors: Muijsers R.B.R.; Goa K.L.